Sessions
THE POTENTIAL & PROMISE OF ALLOGENEIC
THE CONTINUED RISE & APPLICATION OF AUTOLOGOUS THERAPIES
THE EXPONENTIAL GROWTH OF GENE THERAPY & IT’S FUTURE POTENTIAL
THE POTENTIAL & PROMISE OF ALLOGENEIC
15:30 – CHAIR INTRODUCTION
Chair: Mark Lowdell, Chief Scientific Officer, INmune Bio
15:35 – CASE STUDY: TCR-NK: A NOVEL TREATMENT PARADIGM FOR THE TREATMENT OF SOLID CANCERS
Speaker: Namir Hassan, CEO, Zelluna
15:50 – CASE STUDY: TRANSITION FROM AUTOLOGOUS TO FULLY ALLOGENEIC GAMMA-DELTA T CELL THERAPY
Speaker: Michael Leek, Executive Chairman & Founder, TC BioPharm
16:05 – CASE STUDY: PROGRESS TRENDS & FUTURE DIRECTIONS OF ALLOGENEIC THERAPIES
Speaker: Stefanos Theoharis, Chief Business Officer, Bone Therapeutics S.A
16:20 – CASE STUDY: MONITORING ALLOGENEIC CELL MEDICINES IN VIVO – WHAT IS “ENGRAFTMENT” AND IS IT NECESSARY?
Speaker: Mark Lowdell, Chief Scientific Officer, INmune Bio
16:35 – Q&A WITH SESSION SPEAKERS
Speakers:
Namir Hassan, CEO, Zelluna
Michael Leek, Executive Chairman & Founder, TC BioPharm
Stefanos Theoharis, Chief Business Officer, Bone Therapeutics S.A
Speakers
